Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive pregabalin to prevent bortezomib-induced peripheral neuropathy in multiple myeloma
ChiCTR2500101743Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in multiple myeloma (MM) comparing Pregabalin + bortezomib with Placebo + bortezomib (2 arms). Primary endpoint: Incidence of chemotherapy-induced peripheral neuropathy after completion of Phase I chemotherapy. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
pregabalin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500101743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101743.